4basebio PLC announced a Joint Development Agreement with Heqet Therapeutics S.r.l. This JDA is focussed on the development of a non-viral vector, incorporating a proprietary Heqet payload for cardiomyocyte regeneration and treatment of myocardial infarction more broadly. Under the JDA, the companies will evaluate the use of 4basebio's Hermes non-viral nanoparticle for the delivery of payloads targeting cardiomyocyte regeneration. The successful outcome of this project may lead to the proof-of-concept development of a therapy enabling heart regeneration post infarction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,160 GBX | +1.31% | +7.41% | +70.59% |
04-10 | 4basebio to supply synthetic DNA for mRNA vaccine program | AN |
04-10 | 4Basebio plc Announces the Supply of Its opDNA? DNA Products into Tier 1 Pharma Client's Vaccine Program | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+70.59% | 186M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- 4BB Stock
- News 4basebio PLC
- 4basebio PLC Announces Joint Development Agreement with Heqet Therapeutics